Bristol/AstraZeneca's Onglyza Works As Combo In Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials prove saxagliptin controls glucose in type 2 disease.
You may also be interested in...
BMS, AstraZeneca’s Onglyza Enters Murky Regulatory Waters
Scrutiny of potential cardiovascular risks looms over new diabetes drugs.
Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.